Genus plc (LON:GNS – Get Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 2,604.34 and traded as high as GBX 3,125. Genus shares last traded at GBX 3,065, with a volume of 2,605,506 shares changing hands.
Analysts Set New Price Targets
Several equities analysts have recently commented on GNS shares. Shore Capital Group reaffirmed a “buy” rating and issued a GBX 3,000 target price on shares of Genus in a research report on Friday, January 16th. Deutsche Bank Aktiengesellschaft boosted their price target on Genus from GBX 3,100 to GBX 3,300 and gave the company a “buy” rating in a research note on Friday, January 16th. Finally, Berenberg Bank reiterated a “buy” rating and set a GBX 3,350 price objective on shares of Genus in a research report on Thursday, February 5th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of GBX 3,216.67.
View Our Latest Stock Report on GNS
Genus Stock Down 0.5%
About Genus
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
Featured Stories
- Five stocks we like better than Genus
- Think You Missed Silver? You’re Wrong. Here’s Why.
- Is Trump Done? Shocking leak…
- Trump’s AI Secret: 100X Faster Than Nvidia
- Your Bank Account Is No Longer Safe
- Did you hear what Nvidia’s CEO said?
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
